INTRODUCTION
Pre-eclampsia (PE) and fetal growth restriction (FGR) are leading causes of maternal and fetal mortality. [1] [2] [3] Shallow implantation (deficient trophoblast invasion of the maternal spiral arterioles in early pregnancy) leads to impaired placental perfusion that manifests later in pregnancy as preterm PE and FGR. 4 Although the precise pathology of PE and FGR is unknown, exaggerated placental apoptosis has been suggested as a key mechanism in the development of placental dysfunction, associated with severe early onset disease before 34 weeks gestation. 5 Early onset PE and FGR pose the greatest challenge for the clinician. As there are no effective intrauterine treatments, management relies on early detection and timely delivery. 6, 7 However, the benefit of delivery to prevent maternal morbidity and stillbirth must be balanced against the risks of prematurity to the fetus. Current screening tests are inadequate and many cases are diagnosed too late: undetected FGR accounts for up to 50% of potentially preventable stillbirths. 2, 8 Therefore, a reliable screening test could significantly improve clinical outcomes, and a noninvasive biomarker would be ideal. 9 A novel approach to developing biomarkers for pregnancy complications is the use of fetal nucleic acids in the maternal circulation. Nucleic acids of placental origin are released into the maternal blood from early in pregnancy, and can be quantified to potentially provide information about placental function while the fetus remains in-utero. 10, 11 Trafficking of nucleic acids across the placenta may be due to syncytiotrophoblast turnover and cell death (apoptosis) in both normal and complicated pregnancies. 12 It has been proposed that with impaired placental perfusion there is hypoxia-reperfusion injury to the placenta that results in increased apoptosis and release of syncytiotrophoblast microparticles, containing fetal nucleic acids, into the maternal circulation. 13 There is morphological evidence of increased placental apoptosis in PE and FGR, but the expression of genes in the apoptotic pathways are poorly understood. 14, 15 We hypothesized that apoptotic genes would be differentially expressed in the placenta in severe early onset PE and FGR, be detectable in the maternal blood as circulating RNA and may reflect the placental transcriptome. Therefore, in this study we examined the gene expression of the intrinsic pathway in both placenta and maternal blood, to determine if genes regulating placental apoptosis may be potential biomarkers for the detection of early onset PE and FGR.
METHODS

Study participants
were collected before labor and all placental samples collected at prelabor cesarean section.
Severe preterm FGR was defined as FGR (customized birthweight o10th centile), requiring delivery before 34 weeks with antenatal evidence of uteroplacental insufficiency (Asymmetrical growth þ abnormal umbilical artery Doppler velocimetry, ± oligohydramnios or abnormal fetal vessel velocimetry). FGR due to infection, chromosomal or congenital abnormalities and multiple pregnancies were excluded. Both maternal blood and placenta was collected from the FGR cases (n ¼ 20). Women with and without PE were included. PE was defined according to ACOG guidelines: blood pressure 4140 mm Hg systolic or 90 mm Hg diastolic and 40.3 g per day of proteinuria, after 20 weeks gestation. 16 Preterm control blood samples were collected from women (n ¼ 20) with an appropriately grown fetus, at a gestation matched to the FGR cases, but who subsequently delivered appropriately grown (birthweight 20 to 80th centile) fetuses at term without obstetric complications. Preterm placental samples (n ¼ 8) were collected from women delivering preterm (o34 weeks), by prelabor cesarean section, an appropriate grown fetus, in the absence of hypertensive diseases of pregnancy or overt chorioamnionitis.
Sample collection
Peripheral whole-blood samples (2.5 ml) were collected in PAXgene blood RNA tubes (PreAnalytix, Hombrechtikon, Switzerland). As per manufacturers instructions, they were stored at room temperature for 24 h to achieve lysis of the cells, transferred to -20 1C for 24 h, and then stored at À 80 1C until processing.
Placental biopsies were obtained immediately after delivery by cesarean section. Placental biopsies were taken from the maternal side of the placenta, to a depth of 2/3 of the placenta, avoiding the decidua. The biopsies were clear of obvious infarction or calcification. Placental biopsies were washed in sterile phosphate-buffered saline to remove contamination by maternal blood, snap frozen and stored at À 80C until processing.
Real-time quantitative RT-PCR
RNA was extracted from peripheral whole maternal blood using the PAXgene Blood miRNA kit (PreAnalytix) according to manufacturer's instructions, as previously described. 17 Placental RNA was extracted using the mirVana Isolation Kit (Ambion, Austin, TX, USA) according to manufacturer's instructions. Genomic DNA was removed using DNAse treatment, and total RNA eluted and stored at À 80C if not used immediately. RNA concentration and purity were measured using a NanoDrop ND1000 spectrophotometer (Thermo Scientific, Pittsburgh, PA, USA). Reverse transcription of 200 ng RNA for RT-PCR was performed using Superscript Vilo (Invitrogen, Carlsbad, CA, USA) according to manufacturers instructions.
Quantitative gene expression analyses were performed with commercially available Taqman Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA) The RT-PCR was performed in triplicate, with multiple negative controls, on the CFX 384 (BioRad, Foster City, CA, USA), with the following cycling conditions: 50C for 2 min, 95C for 10 min, and 40 cycles of 95C for 15 s, 60C for 1 min, and 72C for 30 s. Relative quantification was determined by the comparative CT method, normalized against GAPDH, GUSB and B2M, and calibrated against the mean expression level of the preterm control group.
Statistical Analysis
All data were statistically analyzed using R version 2.12.0 (http://www. r-project.org) or Graphpad Prism v 5(GraphPad Software Inc. San Diego, CA, USA). Differences in RT-PCR gene expression was assessed using Mann-Whitney U or Kruskal-Wallis test, or where the data were considered normally distributed, the t-test or analysis of variance. Patient characteristics were compared using w 2 where appropriate. Data were presented as mean ± s.d. Significance was defined as Po0.05.
RESULTS
The expression of both pro-and anti-apoptotic genes in the intrinsic apoptosis pathway, was investigated in pregnancies complicated by normotensive FGR, PE and FGR (PEo10th), and PE without FGR (PE 410th). The clinical characteristics of the groups are displayed in Table 1 .
Placental expression Morphological markers of apoptosis have previously been described in pre-eclamptic and FGR placentas, therefore we firstly investigated whether there was differential expression of the intrinsic apoptosis genes in these placentas (Figure 1 ). In all pregnancies complicated by FGR (with and without PE) there was an increased expression of the pro-apoptotic genes BAD (2.2-fold for FGR, Po0.05) and BIM (2.7-fold for FGR, Po0.01) compared with preterm controls. When the pregnancy was complicated by PE but the fetus was well grown (PE410th), there was no significant difference in BAD or BIM expression compared with preterm controls.
With FGR, there was also increased expression of the antiapoptotic genes BCL-XL (3.3-fold, Po0.001), BCL2 (2.2-fold, Po0.01) and Survivin (2.2-fold, Po0.01). This increase was noted in normotensive FGR and PE/FGR. However, only BCL2 (1.6-fold, Po0.05) and BCL-XL (2.5-fold, Po0.05) were increased with PE with a well grown fetus compared with well grown preterm controls. Indication for preterm delivery: bleeding placenta praevia (n ¼ 4), maternal medical condition (n ¼ 2), SROM not suitable for vaginal delivery (n ¼ 2).
Circulating apoptosis RNA in placental dysfunction CL Whitehead et al Expression in the maternal blood Apoptosis of the syncytiotrophoblast releases microparticles containing RNA into the maternal circulation. Therefore, we examined whether the same trends in gene expression in the placenta was also present in the maternal blood, suggesting a placental origin of the circulating RNA (Figure 2) . Indeed, RT-PCR analysis of the apoptosis genes revealed increased expression of BAD (3.3-fold, Po0.01), BIM (2.9-fold, Po0.01), BCL-XL (2.4-fold, Po0.01), BCL2 (2.1-fold, Po0.01) and Survivin (2.0 fold, Po0.05) in pregnancies complicated by FGR. Again this increase was present for all FGR cohorts, regardless of whether there was coexistent PE. However, only BCL2 was increased in women with PE alone (1.8-fold, Po0.05).
Expression in severe FGR
Having demonstrated that increased expression of genes regulating apoptosis occurred predominately with FGR, rather than PE, we examined whether the intrinsic apoptosis pathway was further dysregulated as the severity of FGR increased, as determined by increased umbilical artery resistance. Figure 3 demonstrates increased expression in the maternal blood for all five genes in FGR with absent or reversed end diastolic flow, in the umbilical artery compared with normal umbilical artery resistance (Po0.05). There was a progressive increase in the expression of all genes with increasing severity of FGR, but only BAD, BIM and Survivin where significantly increased (Po0.05) with increased resistance (increased UA PI).
DISCUSSION
Severe early onset FGR, with or without PE, is strongly associated with stillbirth and severe perinatal morbidity.
1,2 Once FGR is detected, ultrasound surveillance improves perinatal outcomes. 18 However, current methods of clinical detection of the growthrestricted fetus in the low risk population have a poor sensitivity and specificity, and there are no good cost effective biomarkers that identify the presence of unsuspected FGR. 6 We have undertaken a novel study to profile the expression of genes regulating the intrinsic apoptosis pathway in the maternal blood and placenta in both PE and FGR. In doing so, we have identified a panel of biomarkers that can detect placental dysfunction, notably severe early onset FGR, while the fetus remains in-utero. Thus, circulating mRNA in the maternal blood may offer a promising noninvasive biomarker of FGR.
Placental insufficiency arises due to reduced trophoblast invasion and deficient conversion of the maternal spiral arteries in early pregnancy. 19 In later pregnancy this results in impaired fusion and increased apoptosis of the syncytiotrophoblast. 20 Apoptosis of the syncytiotrophoblast leads to a continuous shedding of microparticles into the maternal circulation, and it has been proposed that these microparticles may be the source of the placental RNA detectable in the maternal circulation. 21, 22 Interestingly, although there is increased placental apoptosis in both PE and normotensive FGR, previous studies have not shown an increase in the levels of circulating microparticles in FGR. 23 In this study we demonstrate increased expression of circulating RNA for apoptotic genes with increasing severity of FGR, as evidenced by worsening umbilical artery resistance. In placenta from severe early onset FGR with absent or reversed end diastolic flow, there is morphological evidence of increased apoptosis compared with FGR with positive end diastolic flow. 24 In this study, expression of apoptosis genes detectable in the maternal circulation, demonstrates that circulating RNA may not only detects the presence of FGR but also the severity of disease.
Although apoptosis has been described in placental dysfunction, the intrinsic apoptosis pathway is poorly characterized and the few studies to date have produced conflicting results. BCL2 is the most frequently studied marker of apoptosis in placental dysfunction as it localizes to the syncytiotrophoblast and has been shown to be increased in expression in PE and FGR.
14,25 Survivin and BCl-XL have not been studied in FGR but may be increased in PE. 26 BAD and BIM are poorly characterized in placental dysfunction, but are upregulated in the syncytiotrophoblast in response to hypoxia. 27 Interestingly, both pro-and anti-apoptotic genes are upregulated in this and previous studies. This perhaps reflects a disordered regulation of apoptosis in placental dysfunction that is as yet not clearly understood.
Importantly, a strength of our study is the division of our cohort into normotensive FGR, FGR and PE and PE with a well grown fetus. The pathology of these different cohorts may overlap but the clinical management is distinct. Despite this, very few studies differentiate them, whereas we were able to consider them individually. A further problem with previous studies is that FGR may be confused with small-for-gestational age fetuses (constitutionally o10th centile), which are not pathologically growth restricted. In our study, all participants had Doppler velocimetry of the umbilical artery performed, thus ensuring our FGR cohort arose due to placental insufficiency. As preterm FGR has a far stronger association with perinatal mortality than smallfor-gestational age, identifying these pregnancies is clinically essential. 8 In this study we examine the role of circulating RNA coding genes regulating apoptosis in the maternal circulation to diagnose severe early onset FGR and PE. We have shown that genes regulating the intrinsic apoptosis pathway are differentially expressed in severe early onset FGR. These changes are detectable in the maternal blood, may represent the placental transcriptome, and represent the severity of disease. Circulating mRNA may be a useful biomarker of placental function, enabling the identification of pregnancies affected by severe preterm FGR. Further validation with a large prospective study is required to determine the potential to use this novel approach to detect FGR. If successful, a noninvasive diagnostic test that identifies the presence of early onset FGR would allow clinicians to institute appropriate monitoring and to time delivery before the advent of stillbirth. AREDF 
